European Commission Grants Approval for Merck KGaA's OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU

Reuters08-18

European Commission Grants Approval for <a href="https://laohu8.com/S/MKGAF">Merck KGaA</a>'s OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU

Merck KGaA, a leading science and technology company based in Darmstadt, Germany, has announced that the European Commission $(EC)$ has granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. This marks the first and only therapy approved in the European Union for treating desmoid tumors. The approval is a significant advancement for desmoid tumor patients and is based on the successful results of the Phase 3 DeFi trial, which demonstrated a substantial improvement in progression-free survival and objective response rate. The approval was issued to SpringWorks Therapeutics Inc., a healthcare company affiliated with Merck KGaA, underscoring their commitment to the rare tumor patient community.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on August 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2560188894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560188894","market":"fut","top_or_hot":-1,"title":"European Commission Grants Approval for Merck KGaA's OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      European Commission Grants Approval for <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a>'s OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a>, a leading science and technology company based in Darmstadt, Germany, has announced that the European Commission <a href=\"https://laohu8.com/S/EC\">$(EC)$</a> has granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. This marks the first and only therapy approved in the European Union for treating desmoid tumors. The approval is a significant advancement for desmoid tumor patients and is based on the successful results of the Phase 3 DeFi trial, which demonstrated a substantial improvement in progression-free survival and objective response rate. The approval was issued to SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a healthcare company affiliated with Merck KGaA, underscoring their commitment to the rare tumor patient community.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>European Commission Grants Approval for Merck KGaA's OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEuropean Commission Grants Approval for Merck KGaA's OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-18 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      European Commission Grants Approval for <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a>'s OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a>, a leading science and technology company based in Darmstadt, Germany, has announced that the European Commission <a href=\"https://laohu8.com/S/EC\">$(EC)$</a> has granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. This marks the first and only therapy approved in the European Union for treating desmoid tumors. The approval is a significant advancement for desmoid tumor patients and is based on the successful results of the Phase 3 DeFi trial, which demonstrated a substantial improvement in progression-free survival and objective response rate. The approval was issued to SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a healthcare company affiliated with Merck KGaA, underscoring their commitment to the rare tumor patient community.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SWTX","symbol_name":"SpringWorks Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL1lZn54:1","article_id":"2560188894","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560188894","pubTimestamp":1755522322,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Merck KGaA, a leading science and technology company based in Darmstadt, Germany, has announced that the European Commission  has granted marketing authorization for OGSIVEO , an oral gamma secretase inhibitor, as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. This marks the first and only therapy approved in the European Union for treating desmoid tumors. The approval is a significant advancement for desmoid tumor patients and is based on the successful results of the Phase 3 DeFi trial, which demonstrated a substantial improvement in progression-free survival and objective response rate. The approval was issued to SpringWorks Therapeutics Inc., a healthcare company affiliated with Merck KGaA, underscoring their commitment to the rare tumor patient community.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SWTX":"SpringWorks Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"欧盟委员会批准默克公司的OGSIVEO作为欧盟首个治疗硬纤维瘤的药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SWTX":0.9},"content_text":"European Commission Grants Approval for Merck KGaA's OGSIVEO as First-Ever Treatment for Desmoid Tumors in the EU\n    \n\nMerck KGaA, a leading science and technology company based in Darmstadt, Germany, has announced that the European Commission $(EC)$ has granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as a monotherapy for adults with progressing desmoid tumors requiring systemic treatment. This marks the first and only therapy approved in the European Union for treating desmoid tumors. The approval is a significant advancement for desmoid tumor patients and is based on the successful results of the Phase 3 DeFi trial, which demonstrated a substantial improvement in progression-free survival and objective response rate. The approval was issued to SpringWorks Therapeutics Inc., a healthcare company affiliated with Merck KGaA, underscoring their commitment to the rare tumor patient community.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on August 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2560188894","isCrawlerRequest":true}